Ask AI
CLL17
CLL17: Phase III Trial of Continuous Ibrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab or Venetoclax Plus Ibrutinib for Untreated CLL

Released: December 10, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: December 10, 2025